We decided to exit the Oracle position and book a short-term tax loss, spreading the capital across several of the ...
During the fourth quarter, Baron Opportunity Fund posted a return of 4.63% (Institutional Shares), outperforming the Russell ...
Asianet Newsable on MSN
Novo Nordisk reportedly eyes launching Wegovy in vials to compete with rival Eli Lilly
Bloomberg reported on Wednesday, citing Novo CEO Mike Doustdar, that the vials are slated to be introduced in the U.S. this ...
Novo and Lilly are locked in a tightening fight in the obesity-drug market, with Novo trying to win back its crown after a ...
Compare Zepbound and Wegovy to understand how one hormone vs two impacts weight loss, appetite control, side effects, and ...
The Danish drugmaker kicked off 2026 with its explosive obesity pill launch, but recent challenges have centered around protecting its market share.
Despite their huge popularity, GLP-1 injury lawsuits citing the drugs as a cause for a host of severe GI issues and even ...
Eli Lilly is priced for perfection thanks to its GLP-1 drugs, while Wall Street seems to have forgotten about these two ...
When Mike Doustdar started as a summer employee making copies at Novo Nordisk—a teenager living in Austria after fleeing unrest in his home country of Iran at 12—he never imagined he would remain at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results